Autopsy report · NCT01377909

HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity

“Principal Investigator retiring”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 months before it started.
• Ran for about 1 year 5 months before it stopped.
• 20 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Bader, Ted, M.D.

Sponsor type

University, hospital or other

Conditions

Chronic Hepatitis C

Interventions

statin

Participants

20

Sites

1

Countries

United States

Trials that died the same way

• Target Sign vs Palpation for Radial Arterial Line Placement
  “Principal Investigator retired” (93% match in meaning)
• Nutraceuticals Versus Usual Care in the Prevention or Reduction of CIPN in Patients Treated With Docetaxel as Neoadjuvant/Adjuvant Breast Cancer Therapy
  “Retirement of the Principal Investigator” (90% match in meaning)
• The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer
  “Principal Investigator retired before study completed.” (87% match in meaning)
• Phase II Study Using Genomic & Proteomic Profiling to Influence Treatments for Patients With Metastatic Breast Cancer
  “Resignation of Principal Investigator” (82% match in meaning)
• Identification and Characterization of Molecular Markers in Musculoskeletal Tumors
  “Principal Investigator has left the Institution” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.